Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 604

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 5
Chunk 604
---
 with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration
rights related to the shares issued under the 2023 Purchase Agreement.

In consideration for entering
into the 2023 Purchase Agreement, the Company issued 696,021 shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.

During the years ended June 30,
2025 and June 30, 2024 no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.

Common Stock Issuances 

On
April 8, 2025, the Company issued 15,000,000 shares of Common Stock valued at $6,058,500 (see Note 13) pursuant to the Stock Purchase
Agreement of Biosymetrics, Inc.

On January 21, 2025, the Company
issued 250,000 shares of Common Stock to its Chief Executive Officer of Renovaro Cube valued at $177,500.

On October 17, 2024, the Company
issued 160,000 shares of Common Stock for consulting services valued at $119,400.

    F-22

On October 14, 2024, the Company
issued 500,000 shares of Common Stock for consulting services valued at $275,000.

On October 14, 2024, the Company
issued 250,000 shares of Common Stock to its Chief Executive Officer valued at $137,750.

On August 23, 2024, Avram Miller,
a former member of the Company’s board of directors (the “Board of Directors”), forfeited 833,333 shares of
Common Stock from the original 1,000,000 shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase 978,261 shares of Common
Stock of the Company with a per-share exercise price of $0.69. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized